Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Hepatocellular Carcinoma Screening Linked with Curative Treatment and Longer Survival in Cirrhosis Patients

By Medimaging International staff writers
Posted on 24 Apr 2014
Image: Very high magnification micrograph of fibrolamellar hepatocellular carcinoma showing the characteristic laminated fibrosis between the tumor cells with a low N/C ratio. H&E stain (Photo courtesy of Wikimedia Commons).
Image: Very high magnification micrograph of fibrolamellar hepatocellular carcinoma showing the characteristic laminated fibrosis between the tumor cells with a low N/C ratio. H&E stain (Photo courtesy of Wikimedia Commons).
Investigators discovered that patients with cirrhosis who underwent surveillance (using liver ultrasound with or without measurement of serum alpha fetoprotein) for hepatocellular carcinoma (HCC) had cancers detected at an earlier stage, were more likely to receive curative instead of palliative treatment, and had longer survival.

In a systematic review and meta-analysis of 47 studies with 15,158 patients, Dr. Amit Singal, from the University of Texas Southwestern Medical Center (Dallas, USA) and colleagues reported that the pooled thee-year survival rate across all the studies was 50.8% among the 4,735 patients who underwent HCC surveillance, compared to 27.9% among the 6,115 patients without earlier surveillance (p < 0.001).

The finding of longer survival persisted after the authors limited their review to studies that took into account lead time bias. Lead time bias, as it applies to this study, is the time between when a disease would normally be diagnosed without screening and when the disease is diagnosed with screening. Detecting disease earlier through screening can at times seen be to increase survival when instead it only prolongs the time the person has the diagnosis. However, in this case, studies that accounted for lead time bias statistically still found that screening increased survival. Among the six studies that adjusted for lead time bias, those who underwent HCC surveillance had three-year survival rates of 39.7%, vs. 29.1% among those who did not (p < 0.001).

The authors noted that while screening for HCC in patients with Hepatitis B virus (HBV) infection is supported by a large randomized trial, no such randomized trials exist for patients with cirrhosis. Therefore the authors systematically reviewed published research that evaluated whether screening was associated with improved patient outcomes. While guidelines of the American Association for the Study of Liver Diseases and European Association for the Study of the Liver recommend monitoring with ultrasound every six months in high-risk patients (which includes those with chronic HBV infection and/or cirrhosis), the authors noted that studies have shown that surveillance in the United States is performed in less than 20% of these patients nationally, with lower rates among primary care physicians than gastroenterologists/hepatologists (physicians who specialize in caring for patients with liver disease).

A drawback of the study is that the studies were quite heterogeneous, suggesting benefits of surveillance may not be uniform among all patients, and studies did not include functional status, an important factor in determining appropriate treatment.

The authors concluded that, “the preponderance of data that consistently demonstrate benefits should provide sufficient rationale to recommend HCC surveillance, even in the absence of a randomized controlled trial among patients with cirrhosis.”

Related Links:

University of Texas Southwestern Medical Center



view channel
Image: Multimodal CT images obtained 2 hours 18 minutes after symptom onset in an 87-year-old woman with an NIH Stroke Scale of 15 and left hemisphere symptoms (Photo courtesy of Radiology 2015:257;2;510-520, and RSNA 2015).

Faster and Simpler Treatment for Stroke Patients Using Multiphase CT

The results of a new study show that multiphase Computed Tomography (CT) angiography brain-imaging could enable clinicians to treat Acute Ischemic Stroke (AIS) patients faster, and better, potentially saving lives.... Read more


view channel

Study Shows Steep Rise in the Use of MRI Scans Before Breast Cancer Surgery

The results of a new study have shown an eightfold rise in the use of Magnetic Resonance Imaging (MRI) scans before breast cancer surgery in the Canadian province of Ontario between 2003 and 2012. Guidelines on the use of MRI scans before surgery are inconsistent, the study showed, and the increased use of MRI was characteristic... Read more

Nuclear medicine

view channel
Image: The whole body of a rat can be imaged for blood clots with one PET scan, overlaid here on an MRI image, using the FBP8 probe. The arrow points to a blood clot (Photo courtesy of the American Chemical Society).

Single PET Scan Could Replace Multiple Modalities in Detecting Blood Clots

Researchers have presented an experimental technique that could be used to discover blood clots using a single, fast, whole-body scan, at the 250th National Meeting and Exposition of the American Chemical... Read more

General/Advanced Imaging

view channel

Leading Vendor to Implement and Install Enterprise Imaging Platform for UK NHS

An agreement has been announced by a leading imaging platform provider for the implementation of the first Enterprise Imaging platform, part of a long-term agreement for the management of imaging data, for the UK City Hospitals Sunderland NHS Foundation Trust. The agreement covers the capture, storage, and exchange of... Read more

Imaging IT

view channel

Carestream Updates Healthcare IT Platform

Carestream has released updates for an advanced Internet Technology (IT) healthcare platform at the Röntgenveckan Radiology congress in Malmo (Sweden). The IT platform facilitates collaboration by enabling sharing of critical patient information such as Radiology images, videos, reports, and services with groups outside... Read more

Industry News

view channel

New Distribution and Commercialization Agreement for Medical Imaging Contrast Agent in China

China’s second largest pharmaceutical distribution group and an international medical imaging pharmaceutical group have announced an agreement for the distribution and commercialization of Lipiodol Ultra-Fluid, from September 2015. Lipiodol Ultra-Fluid is used in interventional radiology procedures as a contrast agent,... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.